Recently approved vaccines have shown remarkable efficacy in limiting SARS-CoV-2-associated
disease. However, with the variety of vaccines, immunization strategies, and waning …

SARS-CoV-2 variants that attenuate antibody neutralization could jeopardize vaccine efficacy.
We recently reported the protective activity of an intranasally administered spike protein-…

Recently approved vaccines have already shown remarkable protection in limiting SARS-CoV-2
associated disease. However, immunologic mechanism (s) of protection, as well as how …

Omicron SARS-CoV-2 variants escape vaccine-induced neutralizing antibodies and cause
nearly all current COVID-19 cases. Here, we compared the efficacy of three booster vaccines …

Background Although vaccines effectively prevent coronavirus disease 2019 (COVID-19) in
healthy individuals, they appear to be less immunogenic in individuals with chronic …

Despite the rapid creation of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
vaccines, the precise correlates of immunity against severe Coronavirus Disease 2019 (…

The reduced effectiveness of COVID-19 vaccines due to the emergence of variants of concern
(VOCs) necessitated the use of vaccine boosters to bolster protection against disease. …

With the continued emergence of variants of concern, the global threat of COVID-19 persists,
particularly in low- and middle-income countries with limited vaccine access. Protein-based …

Background Vibriocidal antibodies are currently the best characterised correlate of protection
against cholera and are used to gauge immunogenicity in vaccine trials. Although other …

Coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), remains a global public health emergency. Although …